包膜病毒膜融合及其在生物医学中的应用
卞传秀,廖国阳,李卫东,中国医学科学院协和医科大学医学生物研究所 云南省昆明市 650118
杨建勇,卫生部北京生物制品所 北京市 100024
云南省科技厅新药专项基金资助项目,No. 2000XY05
云南省技术创新人才项目,No. 2003PY07
通讯作者:李卫东,650118, 云南省昆明市,中国医学科学院协和医科大学医学生物研究所. imblwd@yahoo.com.cn
电话:0871-8333576 传真: 0871-8334483
收稿日期:2005-04-07 接受日期: 2005-04-09
, http://www.100md.com
摘要
病毒结合到宿主细胞表面受体后，启动了病毒融合蛋白的一系列构象变化，暴露出融合肽，使病毒包膜和细胞膜融合.膜融合使病毒蛋白及病毒RNA基因组释放到宿主细胞内而感染宿主.针对包膜病毒进入细胞的分子机制设计抗病毒药物和疫苗，为防治疾病发生开辟了新的思路.
卞传秀, 杨建勇, 廖国阳, 李卫东. 包膜病毒膜融合及其在生物医学中的应用. 世界华人消化杂志 2005;13(12):1437-1439
Chazal N, Gerlier D. Virus entry, assembly, budding, and membranerafts. Microbiol Mol Biol Rev 2003;67:226-237
2 Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependentendocytosis.Biochem J 2004;377(Pt1):1-16
, 百拇医药
3 Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, WileyDC. Structural basis for membrane
fusion by enveloped viruses. Mol MembrBiol 1999;16:3-9
4 徐耀先, 周小峰,刘立德.分子病毒学.第一版. 武汉:湖北科学技术出版社, 2000:64-72
5 Eckert DM, Kim PS. Mechanisms of viral membrane fusion and itsinhibition. Annu Rev Biochem 2001;70:777-810
6 Tamm LK, Crane J, Kiessling V. Membrane fusion: a structuralperspective on the interplay of lipids and proteins. Curr
, 百拇医药
Opin Struct Biol 2003;13:453-466
7 Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens,antigens, and immunogens. Science 1998;280:
1884-1888
8 Heinz FX, Allison SL. The machinery for flavivirus fusion with hostcell membranes. Curr Opin Microbiol 2001;4:450-455
9 Wiley DC, Skehel JJ. The structure and function of thehemagglutinin membrane glycoprotein of influenza virus.
, 百拇医药
Annu Rev Biochem 1987;56:365-394
10 Freed EO, Myers DJ, Risser R. Characterization of the fusion domainof the human immunodeficiency virus
type 1 envelope glycoprotein gp41. ProcNatl Acad Sci USA 1990;87:4650-4654
11 Smith AE, Helenius A. How viruses enter animal cells. Science 2004;304:237-242
12 王小佳, 张卫红,汪明,高福. 囊膜病毒膜融合的分子机制. 生物化学与生物物理进展 2004;31:482-490
, http://www.100md.com
13 Remeta DP, Krumbiegel M, Minetti CA, Puri A, Ginsburg A, BlumenthalR. Acid-induced changes in thermal stability
and fusion activity of influenzahemagglutinin. Biochemistry 2002;41:2044-2054
14 余勇, 肖庚富,李敏,詹睿, 张文涛.人类免疫缺陷病毒HIV-1进入细胞的分子机制及相关药物的研究.
生物化学与生物物理进展 2003;30:13-17
15 Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ,Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel
, http://www.100md.com
RJ. Single-dose safety, pharmacology,and antiviral activity of the human immunodeficiency virus(HIV)type 1
entry inhibitor PRO 542 inHIV-infected adults. J Infect Dis 2000;182:326-329
16 张颖, 白雪帆,李靖,张岩, 王九平,孙永涛,黄长形.淋巴细胞HIV-1辅受体表型剔除阻断病毒感染的研究.
中华微生物学和免疫学杂志 2004;24:72-75
17 Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D.Enfuvirtide: the first therapy to inhibit the entry
, 百拇医药
of HIV-1 into host CD4 lymphocytes. NatRev Drug Discov 2004;3:215-225
18 Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S,Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger
H, Parren PW, Robinson J, Van Ryk D,Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, ArthosJ.
HIV-1 evades antibody-mediatedneutralization through conformational masking of receptor-binding sites.
, 百拇医药
Nature 2003;420:678-682
19 Fang F, Yu M. Viral receptor blockage by multivalent recombinantantibody fusion proteins: inhibiting human
rhinovirus (HRV) infection withCFY196. J Antimicrob Chemother 2004;53:23-25
20 Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, YuC, Arkin MR, Raimundo BC. Discovery of a
potent small molecule IL-2 inhibitorthrough fragment assembly. J Am Chem Soc 2003;125:3714-3715
, 百拇医药
21 Pollack P, Groothuis JR. Development and use of palivizumab(Synagis): a passive immunoprophylactic agent for RSV.
J Infect Chemother 2002;8:201-206
22 Hogle JM, Chow M, Filman DJ. Three-dimensional structure ofpoliovirus at 2.9 A resolution. Science 1985;229:
1358-1365
23 Dimitrov DS. Virus entry: molecular mechanisms and biomedicalapplications. Nat Rev Microbiol 2004;2:109-122
24 Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-GonzalezJF, Salazar MG, Kilby JM, Saag MS,Komarova NL, Nowak MA, Hahn BH, KwongPD, Shaw GM. Antibody neutralization and escape by HIV-1.
Nature 2003;422:307-312
编辑 王谨晖 审读 张海宁, 百拇医药( 卞传秀,杨建勇,廖国阳,李卫东)
杨建勇,卫生部北京生物制品所 北京市 100024
云南省科技厅新药专项基金资助项目,No. 2000XY05
云南省技术创新人才项目,No. 2003PY07
通讯作者:李卫东,650118, 云南省昆明市,中国医学科学院协和医科大学医学生物研究所. imblwd@yahoo.com.cn
电话:0871-8333576 传真: 0871-8334483
收稿日期:2005-04-07 接受日期: 2005-04-09
, http://www.100md.com
摘要
病毒结合到宿主细胞表面受体后，启动了病毒融合蛋白的一系列构象变化，暴露出融合肽，使病毒包膜和细胞膜融合.膜融合使病毒蛋白及病毒RNA基因组释放到宿主细胞内而感染宿主.针对包膜病毒进入细胞的分子机制设计抗病毒药物和疫苗，为防治疾病发生开辟了新的思路.
卞传秀, 杨建勇, 廖国阳, 李卫东. 包膜病毒膜融合及其在生物医学中的应用. 世界华人消化杂志 2005;13(12):1437-1439
Chazal N, Gerlier D. Virus entry, assembly, budding, and membranerafts. Microbiol Mol Biol Rev 2003;67:226-237
2 Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependentendocytosis.Biochem J 2004;377(Pt1):1-16
, 百拇医药
3 Weissenhorn W, Dessen A, Calder LJ, Harrison SC, Skehel JJ, WileyDC. Structural basis for membrane
fusion by enveloped viruses. Mol MembrBiol 1999;16:3-9
4 徐耀先, 周小峰,刘立德.分子病毒学.第一版. 武汉:湖北科学技术出版社, 2000:64-72
5 Eckert DM, Kim PS. Mechanisms of viral membrane fusion and itsinhibition. Annu Rev Biochem 2001;70:777-810
6 Tamm LK, Crane J, Kiessling V. Membrane fusion: a structuralperspective on the interplay of lipids and proteins. Curr
, 百拇医药
Opin Struct Biol 2003;13:453-466
7 Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens,antigens, and immunogens. Science 1998;280:
1884-1888
8 Heinz FX, Allison SL. The machinery for flavivirus fusion with hostcell membranes. Curr Opin Microbiol 2001;4:450-455
9 Wiley DC, Skehel JJ. The structure and function of thehemagglutinin membrane glycoprotein of influenza virus.
, 百拇医药
Annu Rev Biochem 1987;56:365-394
10 Freed EO, Myers DJ, Risser R. Characterization of the fusion domainof the human immunodeficiency virus
type 1 envelope glycoprotein gp41. ProcNatl Acad Sci USA 1990;87:4650-4654
11 Smith AE, Helenius A. How viruses enter animal cells. Science 2004;304:237-242
12 王小佳, 张卫红,汪明,高福. 囊膜病毒膜融合的分子机制. 生物化学与生物物理进展 2004;31:482-490
, http://www.100md.com
13 Remeta DP, Krumbiegel M, Minetti CA, Puri A, Ginsburg A, BlumenthalR. Acid-induced changes in thermal stability
and fusion activity of influenzahemagglutinin. Biochemistry 2002;41:2044-2054
14 余勇, 肖庚富,李敏,詹睿, 张文涛.人类免疫缺陷病毒HIV-1进入细胞的分子机制及相关药物的研究.
生物化学与生物物理进展 2003;30:13-17
15 Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ,Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel
, http://www.100md.com
RJ. Single-dose safety, pharmacology,and antiviral activity of the human immunodeficiency virus(HIV)type 1
entry inhibitor PRO 542 inHIV-infected adults. J Infect Dis 2000;182:326-329
16 张颖, 白雪帆,李靖,张岩, 王九平,孙永涛,黄长形.淋巴细胞HIV-1辅受体表型剔除阻断病毒感染的研究.
中华微生物学和免疫学杂志 2004;24:72-75
17 Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D.Enfuvirtide: the first therapy to inhibit the entry
, 百拇医药
of HIV-1 into host CD4 lymphocytes. NatRev Drug Discov 2004;3:215-225
18 Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S,Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger
H, Parren PW, Robinson J, Van Ryk D,Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, ArthosJ.
HIV-1 evades antibody-mediatedneutralization through conformational masking of receptor-binding sites.
, 百拇医药
Nature 2003;420:678-682
19 Fang F, Yu M. Viral receptor blockage by multivalent recombinantantibody fusion proteins: inhibiting human
rhinovirus (HRV) infection withCFY196. J Antimicrob Chemother 2004;53:23-25
20 Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, YuC, Arkin MR, Raimundo BC. Discovery of a
potent small molecule IL-2 inhibitorthrough fragment assembly. J Am Chem Soc 2003;125:3714-3715
, 百拇医药
21 Pollack P, Groothuis JR. Development and use of palivizumab(Synagis): a passive immunoprophylactic agent for RSV.
J Infect Chemother 2002;8:201-206
22 Hogle JM, Chow M, Filman DJ. Three-dimensional structure ofpoliovirus at 2.9 A resolution. Science 1985;229:
1358-1365
23 Dimitrov DS. Virus entry: molecular mechanisms and biomedicalapplications. Nat Rev Microbiol 2004;2:109-122
24 Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-GonzalezJF, Salazar MG, Kilby JM, Saag MS,Komarova NL, Nowak MA, Hahn BH, KwongPD, Shaw GM. Antibody neutralization and escape by HIV-1.
Nature 2003;422:307-312
编辑 王谨晖 审读 张海宁, 百拇医药( 卞传秀,杨建勇,廖国阳,李卫东)
